FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
July 02, 2024 at 14:04 PM EDT
It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.
